Challenges and clinical relevance of molecular detection of Bordetella pertussis in South Africa
- PMID: 30898099
- PMCID: PMC6429695
- DOI: 10.1186/s12879-019-3869-7
Challenges and clinical relevance of molecular detection of Bordetella pertussis in South Africa
Abstract
Background: We assessed the utility of a multi-target, real-time PCR assay for Bordetella pertussis detection and diagnosis in patients with severe respiratory illness (SRI), influenza-like illness (ILI), and asymptomatic controls.
Methods: Real-time PCR detection of IS481, pIS1001, hIS1001 and ptxS1 was performed on nasopharyngeal specimens (SRI, ILI and controls) and induced sputum (SRI) collected from June 2012 to May 2016 through respiratory illness surveillance. Using PCR cycle threshold (Ct) value cut-offs, IS481 positive cases were classified as confirmed (Ct < 35) or possible (Ct 35-39) pertussis disease.
Results: Among 12,922 samples, 146 (1.1%) were IS481 positive of which 62% (90/146) were classified as confirmed. The attributable fraction (AF) was 92.2% (95% CI, 65.6 to 98.2%) and 90.5% (95% CI, 57.5 to 97.9%) amongst SRI and ILI PCR-confirmed pertussis cases, respectively. Amongst possible pertussis cases, AF was 36.9% (95% CI, - 142.3 to 83.6%) and 67.5% (95% CI, - 30.6 to 91.9%) in the SRI and ILI groups, respectively.
Conclusion: All IS481 positive specimens could be considered as B. pertussis infection, and potentially pertussis disease with supportive clinical information.
Keywords: Attributable fraction; Bordetella pertussis; Confirmed-pertussis; Influenza-like illness (ILI); Possible-pertussis; Real-time PCR; Severe respiratory illness; South Africa; Surveillance.
Conflict of interest statement
Ethics approval and consent to participate
Ethics for SRI (M081042) and ILI (M120133) surveillance and
Consent for publication
Not applicable.
Competing interests
Halima Dawood has received honoraria/travel grants from Pfizer-South Africa, MSD329 South Africa and Mylan-South Africa. Anne von Gottberg has previously received grants from the US Centers for Disease Control and Prevention and Pfizer-South Africa. All other authors declare that they have no commercial or other association that may pose a conflict of interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
